Chimeric Antigen Receptor (CAR) gene therapy, one of the gene-engineered T-cell therapies, is essentially the same as T-Cell Receptor gene therapy but with a different recombinant receptor structure. CAR gene is artificially constructed by combining a single chain variable fragment derived from antibodies that specifically recognize certain antigens expressed on the surface of malignant cells, and cytoplasmic domain(s) required for lymphocyte activation. The genetically engineered CAR T-lymphocytes can recognize the antigens on the cell surface and attack the malignant cells.
RetroNectin®, a recombinant human fibronectin fragment, used in the manufacturing process, leads to highly efficient gene transduction.

Note : As for RetroNectin® , please refer to the following link below.

Mode of action

Redirected CAR T-lymphocytes to the surface antigen of malignant cells exert cytotoxicity by the following steps:

  • Tumor antigen specific CAR is expressed on the cell surface by transducing CAR gene into T-lymphocytes.
  • The expressed CAR molecules recognize antigens on the target malignant cells. Subsequently, signal transduction is activated within gene-transduced T-lymphocytes, and antitumor activity to malignant cells is exerted by release of cytotoxic molecules.
CAR Gene Therapy Projects

We are planning to initiate new clinical trial for next-generation CAR-T therapy targeting CD19 (Product code: TBI-2001) and also for the next-generation CAR-T products which recognize the antigen expressed in solid tumor.

Project / Product Recognize antigen Signal transduction domain Target cancer Status
CD19 CD28-ΔIL2RB-CD3ζ (YXXQ) Blood cancer Pre-clinical
*Undisclosed target CD28-ΔIL2RB-CD3ζ (YXXQ) Solid tumor Pre-clinical
Reference information

Kagoya Y, Tanaka S, Guo T et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018 March 24(3): 352-359

Information of academic conferences
Conference Title
The 28th Annual Meeting of Japan Society of Gene and Cell Therapy
July 14 - 16, 2022
Fukuoka, Japan
Comparability assessment after transfer of the manufacturing process for a next generation CAR-T (CD19-JAK/STAT CAR-T, TBI-2001)

return to top